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Background and objectives: In the present study, clinical criteria used by Spanishnephrologists
when approaching chronic kidney disease (CKD) in kidney recipients, as well as their level
of maintenance and control of renal function, were evaluated.
Methods: An epidemiological, observational, multicenter, nation-wide, prospective study
was carried out, with a 6-month follow-up period. Three hundred and sixty-eight adult
patients with stage 3 kidney disease after a 24-month or longer post-transplantation follow-
up period were included. Visits schedule included a retrospective visit, a baseline visit, an
optional mid-term visit, and a ﬁnal visit at month 6.
Results: Mean time since kidney transplantation was 8.2±5.4 years. Most common pre-
transplant cardiovascular risk factors were high blood pressure (80.2%), followed by high
cholesterol levels (61.7%). Serum creatinine levels showed a statistically signiﬁcant decrease
frombaseline visit to 6-month visit (0.06±0.22; p< .0001), and glomerular ﬁltration rate (GFR)
reduction was −1.03±6.14 (p=0.0014). Signiﬁcant independent prognostic factors for GFR
worseningwere: higher 24-h proteinuria (OR=1.001 permg; p= .020), longer time since trans-
plantation (OR=1.009 per month; p= .017), and lower hemoglobin levels (OR=1.261 per g/dl;
p= .038). Donor age also had some negative inﬂuence (OR=1.021 per year; p= .106). Biop-
sies were obtained in only 8% of kidney transplant recipients with stage 3 CKD with anintervention being carried out in 25.4% of cases.Conclusions: Secondary markers and factors resulting in CKD progression, particularly ane-
mia, are still frequently uncontrolled after kidney transplantation. Only about 2% of patients
beneﬁt from a therapeutic intervention based on a biopsy. Clinical perception differs from
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objective measures, which results in an obvious clinical inertia regarding risk factor control
in such patients.
© 2015 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Actitud clínica frente a la disfunción renal en receptores de un trasplante
renal en Espan˜a
Palabras clave:
Trasplante renal
Tratamiento de la disfunción
renal crónica
Actitud clínica
r e s u m e n
Antecedentes y objetivos: El presente estudio ha evaluado el criterio clínico que utilizan los
nefrólogos espan˜oles frente a la disfunción renal crónica (DRC) en receptores de trasplante
renal (TR), y el grado de mantenimiento y control de la disfunción renal.
Métodos: Estudio observacional, epidemiológico, multicéntrico, nacional y prospectivo, con
un período de seguimiento de 6meses. Se incluyeron 368 pacientes adultos con disfunción
renal de grado3 con un período mínimo de evolución posterior al trasplante de 24meses.
La programación de las visitas incluyó una visita retrospectiva, una visita inicial, una visita
intermedia opcional y una visita ﬁnal al sexto mes.
Resultados: El tiempomedio desde el TR fue de 8,2±5,4 an˜os. La hipertensión (80,2%), seguida
por la hipercolesterolemia (61,7%), fueron los factores de riesgo cardiovascular previos al
trasplantemás frecuentes. Las concentraciones de creatinina sérica entre la visita inicial y la
visita de los 6meses mostraron una diferencia estadísticamente signiﬁcativa de 0,06±0,22
(p<0,0001), y la diferencia del ﬁltrado glomerular (FG) fue de −1,03±6,14 (p=0,0014). Los
factores pronósticos independientes signiﬁcativos del empeoramiento del FG fueron: pro-
teinuria a 24h más alta (OR=1,001 por cada mg; p=0,020), más tiempo desde el trasplante
(OR=1,009 por cada mes; p=0,017) y concentraciones bajas de hemoglobina (OR=1,261 por
cada g/dl; p = 0,038). También se observó cierta inﬂuencia negativa de la edad del donante
(OR=1,021 por cada an˜o; p=0,106). Solo se realizó biopsia en el 8% de los casos de receptores
de TR con DRC de grado 3, suponiendo alguna intervención en el 25,4% de los casos.
Conclusiones: Con frecuencia los marcadores secundarios y los factores de progresión de la
DRC siguen sin estar controlados después del TR, principalmente la anemia. Solo aproxi-
madamente el 2% de pacientes se beneﬁcian de una intervención terapéutica basada en una
biopsia. Existe una disparidad entre la percepción clínica y los parámetros objetivos, que
conduce a una clara inercia clínica del control de los factores de riesgo de estos pacientes.
© 2015 Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española de
Nefrología. Este es un artículo Open Access bajo la licencia CC BY-NC-ND
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here has been a recent progress in immunosuppressive
reatment, however long term survival for kidney transplant
atients has not increased signiﬁcantly over the last ten years.
Chronic kidney disease (CKD) in kidney transplant patients
KT) is a frequent complication, the treatment of which is not
sually simple, since it depends, largely, on the clinical symp-
oms of each patient and the severity of the dysfunction. CKD
s related to various factors; such as the characteristics of the
ransplant (donor, conservation), the speciﬁc features of the
ecipient, the immunosuppression treatment and the clinical
utcome of the transplant.1
The most frequent causes of loss or kidney transplant fail-
re are CKD or death of the patient with functional kidney
ransplant. This is, observed at a rate of 3–5% per year.2CKD in kidney transplant is deﬁned by a gradual deterio-
ation of kidney function, with interstitial ﬁbrosis and tubular
trophy that causes proteinuria, high blood pressure, and a(http://creativecommons.org/licenses/by-nc-nd/4.0/).
gradual increase of serum creatinine. Mild CKD (grade I of
Banff) is observed in nearly all transplants at the end of the
ﬁrst year of transplantation, and grade II and III, is present in
90% of patients ten years after transplant.3
Several studies in patients including biopsies performed
periodically have shown that some parameters of measure-
ment of kidney function (e.g., creatinine) underestimate the
severity of CKD. Therefore, biopsies are an essential tool for
an accurate diagnosis of CKD.3,4
The gradual deterioration of the kidney function is
often accompanied by complications related to the pres-
ence of kidney failure (proteinuria, high blood pressure,
diabetes, hyperlipidemia, anemia, metabolic acidosis, hyper-
phosphatemia, etc.).5–7 As it has been shown in several cohort
studies of KT. Many patients with CKD have accelerated risk
of deterioration of KT function as a consequence of these
comorbidities.8 The adequate treatment for these compli-
cations and the prevention CKD progression require more
attention by the nephrologists.8 As an example, in CKD associ-
ated tone phrotoxicity induced by calcineurin inhibitors (CNI),
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the possibility of reduced exposure by means of decreasing
the dosage of CNI, or even discontinuation if possible, must
be considered.9
The objective of this study was to assess the nephrologist’s
clinical approach to kidney dysfunction in kidney transplant
patients subjected to maintenance treatment. Additionally, it
was assessed the treatment and control of markers and fac-
tors that favors progression of kidney dysfunction, such as
hypertension, urine protein and anemia, and the presence of
cardiovascular risk factors in these patients.
Patients and methods
A non-interventional, multicentre, national and prospective
study was carried out, with a follow-up period of six months.
Initially, 446 adult kidney transplant recipients in mainte-
nance treatment were included, between March 2009 and
March 2010. Of these, 368 were ultimately included for ﬁnal
assessment in this study.
Patients included had to be recipients of a simple kid-
ney transplant, adult, with CKD-3 grade 3 according to the
new guidelines K/DOQI, Kidney/Disease Outcomes Quality
Initiative (glomerular ﬁltration rate, GF of 30–59ml/min),
having completed a minimum period of 24 months of trans-
plantation, and having granted their consent to participate
in the study. The K/DOQI guidelines recommend an esti-
mation of the glomerular ﬁltration rate with the MDRD
formula.10 The exclusion criteria were: presence of dual or
multiorganic kidney transplant recipients, and chronic kid-
ney disease of grade 3 (Banff scale) according to kidney graft
biopsy.
Schedule of visits included a retrospective visit (between
6 and 9 months earlier), a starting visit (month 0), an
optional intermediate visit and a ﬁnal visit (month 6). All
patients signed the informed consent to participate in the
study. A Clinical Research Ethics Committee authorized
the study, which was carried out according to the Declaration
of Helsinki.
The information included in the present study was
obtained by means of personal interviews with the patient
and data collection from clinical history in 47 outpatient
kidney transplant clinics from hospitals in Spain. The infor-
mation of interest was: demographic data of patients and
their medical history, aetiology of the terminal kidney failure
(TKF), cardiovascular risk factors prior transplantation, clin-
ical evolution of the transplant, age and sex of the donor,
level of CKD analysed retrospectively, and at initial, intermedi-
ate (optional) and ﬁnal visits, presence of secondary markers
of CKD (proteinuria, serum creatinine level, GFR, blood pres-
sure, haemoglobin level), blood analysis data, induction t and
immunosuppression treatment at discharge.
Additionally, a detailed history was obtained after trans-
plantation, including information about clinical data of
interest after transplantation (i.e., acute rejection, diabetes,
hypertension and malignancies), diagnosis of CKD, kidney
biopsies performed, immunosuppression and other medica-
tions. Further, treatment of comorbidites was also recorded.
During the ﬁnal visit, information was gathered about the
morbidity andmortality of the patient during the studyperiod.;35(3):256–263
The objective criteria to assess the control of comorbidities
was based on according to the corresponding guidelines
of reference: diabetes (blood sugar level while fasting
<120mg/dl)11; hypertension (bloodpressure <130/85mmHg)12;
mineral metabolism (Ca: 8.4–9.5mg/dl, P: 2.7–4.6mg/dl,
iPTH<6.5pg/ml)13; hypercholesterolemia (LDL choles-
terol < 100mg/dl and HDL>40mg/dl in males and >46mg/dl
in females); hypertriglyceridemia ≤200mg/dl).14 Finally, an
questionnaire was given to the nephrologists to provide
an opinion about the changes they made in the immunosup-
pression therapy so the clinical approach of the physician
could be assessed.
Statistical analysis
A descriptive analysis was made of the initial demographic
and clinical variables of all the patients included in the study.
The prevalence and the 95% conﬁdence interval (CI) asso-
ciated with the qualitative variables were calculated in the
retrospective, initial, intermediate and ﬁnal visits. This serve
to compare frequencies and means between variables. The
Kappa coefﬁcientwasused to assess the concordancebetween
the diagnostic criteria established according to the clinical
criteria and according to the objective functional criteria for
the CKD markers.
Student’s t test, ANOVA for repeated measurements or
Wilcoxon test, was used depending on the characteristics of
each variable. McNemar’s test was used for comparisons
of qualitative variables.
A multiple regression analysis was used to determine the
factors that predict of worsening of GFR. This analysis was
based on patients showing a GFR ≥10% in relation to the ini-
tial visit (n = 67). In the multiple regression analysis, all the
demographic and clinical variables which were close to statis-
tical signiﬁcance in prior univariate regressions (p<0.1) were
included. A logistic procedure was used to extract the variabil-
ity step by step, with goodness-of-ﬁt assessment by means of
the Hosmer and Lemeshow tests.
The data were analyzed using the version 9.1 or later of the
statistical software SAS.
Results
Out of the initial sample of 446 identiﬁed patients, a total of
368 patients with CKD of grade 3 (82.51%) met all the inclusion
criteria and none of the exclusion criteria, and were ﬁnally
included in the analysis of the present work.
Demographic and descriptive data
Mean age of patients was 55.6±12.9 years and 61.7% were
males (Table 1). The average time since kidney transplant
was 8.2±5.4 years. The most frequent case of terminal kid-
ney failure (TKF) was chronic glomerulonephritis, which was
observed in 114 cases (31.0%), whereas only one patient
(0.3%) was found to have nephrotoxicity. Hypertension (80.2%)
followed by anemia (34.5%) were the most frequent cardio-
vascular risk factors before transplantation; other risk factors
nefrolog ia. 2015;35(3):256–263 259
Table 1 – Initial characteristics of the sample.
Total
Kidney recipients
Gender, male (%) 227 (61.7)
Age (years), mean (SD) 55.6 (12.9)
Donor
Gender, male (%) 211 (57.3)
Age (years), mean (SD) 47.5 (16.4)
Time since transplant
Mean (±SD), years 8.2±5.4
First transplant 297 (80.7%)
Second transplant 50 (16.3%)
Third transplant 4 (1.1%)
PAR prior to transplant
0% 281 (76.4%)
Between 0 and 10% 20 (5.4%)
Between 10% and 20% 6 (1.6%)
20% or more 16 (4.4%)
No. of HLA incompatibilities
0 2 (0.5%)
1 14 (3.8%)
2 59 (16.0%)
3 102 (27.7%)
4 132 (35.9%)
5 50 (13.6%)
6 9 (2.5%)
Cardiovascular risk factors (CVRF)
High blood pressure 295 (80.2%)
Hypercholesterolaemia 227 (61.7%)
Urine protein 161 (43.8%)
Anemia 127 (34.5%)
Obesity 104 (28.3%)
Hypertriglyceridaemia 85 (23.1%)
Diabetes mellitus 82 (22.3%)
Patients with ≥1 CVRF prior to transplant 331 (90.0%)
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Fig. 1 – Evolution of renal function.Abbreviations: SD: standard deviation, PRA: proﬁle of reactive anti-
bodies; HLA: Human Leukocyte Antigen.
ere dyslipidemia (22.8%) and prior cardiovascular disease
3.5%).
idney function and other clinical assessment
he initial serum creatinine concentration and the glomerular
ltrate (GFR) were 1.6±0.3mg/l and 43.6±7.6ml/m, respec-
ively. At the time of inclusion, 24h urine protein collected
as 425.7±639.9mg (25.5%of patients hadmore than 300mg),
9.7% of patients presented anemia, 89.7% hypertension and
6.1% diabetes.
A statistically signiﬁcant increase in serum creatinine
0.06±0.22mg/dl, p<0.0001) was observed from the initial
o month 6 visit. In the case of GFR, the difference was
1.03±6.14ml/min (p=0.0014) (Fig. 1). From initial visit and
onth 6 a reduction of GFR of more than 18% was observed
n18.2% of patients. Nephropathy from BK virus was investi-
ated in 32.6% of patients.Neoplasia was diagnosed in 9.8% (n=36) of transplanted
atients and the immunosuppression therapy was modiﬁed
n 26 patients (72.2%). A.14.7% of patients (n=54) experienced
ardiovascular complications: most frequent complicationwas angina (27.8%)„ peripheral arterial disease was observed
in 22.2%.
Immunosuppression treatment and biopsies
Treatment for proteinuria, anemia and hypertension was
set in 34.2%, 34.0% and 86.4% of patients and the treat-
ment was strengthened in 60–73% of the uncontrolled
patients. Despite treatment, at month 6, 26.1%, 7.3% and
64.7% of patients did not meet the treatment objec-
tives for proteinuria, anemia and hypertension respectively.
During follow-up, no signiﬁcant changes were observed
in the treatment for immunosuppression (Fig. 2). The
most frequently used immunosuppression drug was cal-
cineurin inhibitors (CNI) combined with anti-metabolites and
esteroids.
A biopsy was performed after transplantion in 28 patients
(7.6%), and the most frequent ﬁnding was chronic rejection
(n=8). The biopsy led to modiﬁcation of therapy in 25.4% of
cases; change in immunosuppression was the most frequent
intervention (50.0%). In 83.3% of patients kidney function
stabilize after modiﬁcation of treatment. The biopsy was pre-
scribed following clinical criteria in all cases, and according to
the opinion of the physicians the biopsy was useful in 88.9%
of cases. Physicians also considered that the techniques of
immunohistochemistry and immunoﬂuorescence were very
260 nefrolog ia. 2015;35(3):256–263
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Fig. 2 – Changes in immunosuppressive treatment.useful to decide therapeutic strategies directed to stabilise
kidney function (88.9% of cases).
Clinical approach of doctors
The nephrologist questionnaire shows that 88.1% of doctors
used the level of proteinuria as a CKD marker, and more than
58% used anemia and hypertension in the same way. In addi-
tion, 80.6% of doctors calculated the change of GFR during the
last year to assess the kidney function deterioration. Doctors
have identiﬁed hypertension, dyslipidaemia, and hypergly-
caemia as equally and clinically adequate factors to assess
the evolution of CKD (91.7%; 91.7% and 88.9%; respectively).
In the case of hypertension, most patients had a reduction
of anti-calcineurin and an increase in mycophenolate (58.3%)
with reduction or discontinuation of esteroids (both 66.7%).
In the case of hyperglycaemia, the priority change was the
reduction of treatment with esteroids (88.3%) or its interrup-
tion (80.6%). Finally, in the case of dyslipidaemia, the priority
change was the reduction of treatment with esteroids (83.3%),
and its interruption in 83.3% of cases.
A 80.6% of the doctors considered that the kidney trans-
plant recipients with CKD required a more intense control
of cardiovascular risk factors, with blood more frequent bio-
chemistries and echocardiograms.
With regard to the control of secondary markers of
CKD, there were no signiﬁcant differences in hypertension
(p=0.513), nor in the urine protein rates or of urine protein
24h (p=0.879) between patients during the visits.
Prognostic factors of GF worsening
The model of multivariate logistic regression (Fig. 3) showed
that the signiﬁcant independent prognostic factors of GFR
worsening were: 24h proteinuria (OR=1.001 per each mg,
p=0.020), period of time elapsed since transplantation
(OR=1.009 per each month, p=0.017) and low haemoglobin
(Hb)evel (OR=1.261 per each g/dl, p=0.038). Also, a negativeinﬂuence of the donor’s age was observed (OR=1.021 per each
year, p=0.106).
Management of CKD
In the initial visit, approximately one third of the patients
had an appropriate management of proteinuria, 89.3%
in had controlled hypertension, and only 37.7% received
optimal treatment of anemia. Physicians failed to treat pro-
teinuria, hypertension and anemiain 31.3%, 18.6% and 16.7%
of the cases respectively.
In the initial visit, there was a 27.3% of patients with good
control of mineral metabolism, 20.3% with acceptable control
of diabetes and 72.9% with controlled cholesterol. In the ﬁnal
visit at month 6, only 16 patients had no appropriate con-
trol of mineral metabolism parameters; 37.5% of patients and
an intensiﬁed control of these parameters. In the case of dia-
betes and hypercholesterolemia, there was an intensiﬁcation
of control in approximately 65%of the previously uncontrolled
patients.
The cardiovascular risk factors such as glucose, glycosy-
lated haemoglobin, blood sugar levels, HDL cholesterol, LDL
cholesterol, total cholesterol and triglycerides, remained sta-
ble throughout all the visits.
There is disparity between the clinical perception and the
objective parameters, which leads to a clear clinical inertia
with respect to control of associated risk factors, hyperten-
sion and proteinuria (Table 2). Regarding hypertension, the
perception of good control by the doctor was greater than
the actual objective parameters gathered from the patient
sheet (81.3% compared to 29.7%). Therefore, the Kappa coefﬁ-
cient of concordance was quite low and non-signiﬁcant, with
values between 0.0762 in the initial visit and 0.1438 in the ﬁnal
visit.
The perception of good control of proteinuria by doctors
was greater (82.3%) than the objective parameters (49.2%). In
this case, the coincidence between clinical perception and the
objective parameters was greater than in hypertension, with
a Kappa coefﬁcient close to 0.5 in all visits.
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0.992 (0.962-1.022)
1.021 (0.996-1.047)
1.013 (0.99-1.036)
0.996 (0.961-1.033)
1.009 (1.002-1.016)
0.623 (0.278-1.395)
0.77 (0.232-2.563)
1.001 (1-1.001)
1.003 (0.998-1.008)
0.793 (0.638-0.987)
0.739 (0.332-1.647)
1.292 (0.695-2.403)
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Finally, the clinical perception of good control of anemia
orresponded almost completely with the objective criteria
85.1% compared to 89.1%); the coincidence increased between
he retrospective and the ﬁnal visits.
A 15–32% of patients who needed initial treatment for
ypertension and proteinuria were not objectively controlled.
All patients were subjected to changes in their treatment
nd to another visit after the transplant. The main reason for
hanges in the treatment was the presence of comorbidities
12.5%). Different specialists were consulted in 14.1% of cases,
ostly endocrinologists. An additional unforeseen visit was
cheduled in25.8% of patients. In the ﬁnal visit, a Doppler
ltrasound of the transplanted kidney was performed in
patients, and there were 13 transplant obtained.
iscussione have carried out a non-interventional, prospective study
o assess the clinical approach of doctors in the treatment
f patients with CKD maintained with a kidney transplant in
pain.
Table 2 – Degree of control of risk factors of kidney dysfunction
High blood pressure Good control according to do
Good control according to ob
Urine protein Good control according to do
Good control according to ob
Anemia Good control according to do
Good control according to ob
Good control according to objective parameters or conﬁrmed: PAS/PAD<1of deterioration of glomerular ﬁltration rate.
Our main results show that hypertension and anemia are
the most frequent cardiovascular risk factors observed before
transplantation. We also show that there are secondary mark-
ers of CKD that cannot be controlled after transplantation,
mainly anemia, which persists without adequate treatment.
Actually, our data shows that there is a 16.7% of patients with-
out intensiﬁed treatment for anemia and this represents a
considerable clinical inertia with major implications in the
progression of CKD, with a low initial rate of adequate treat-
ment of anemia (37.7%). This situation is similar to that
observed in recent prospective studies, showing that the con-
trol of haemoglobin values reduces the progression of chronic
kidney disease in allotransplant KT patients.15,16
A biopsy was obtained only in a limited number of cases
of KT recipients with CKD grade 3, this is in contrast with
recent data published suggesting theneed for biopsies in these
type of.3,4,17 The biopsy results led to therapeutic intervention
in only 25.4% of patients who underwent this procedure, a
percentage which may be considered low according to recent
recommendations.17
Several studies evaluating results from kidney biopsies
have shown that the use of serum creatinine concentration
(hypertension, urine protein and anemia) in the ﬁnal visit.
Final visit (month 6)
ctor 81.3%
jective parameters 29.6%
ctor 82.3%
jective parameters 49.2%
ctor 85.1%
jective parameters 89.1%
30/80mmHg; urine protein 24h ≤300mg/24h; hemoglobin>11g/dl.
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for the diagnosis of nephropathy may lead to underestimation
of the severity of CKD.18 According to some authors, biopsy is
a procedure recommended in patients with serum creatinine
concentrations increased by more than 20% of the minimum
creatinine concentration during the last 3–6 months, regard-
less of the presence of proteinuria.19
In our study, a graft biopsy was performed in 7.6% of
patients between the initial and ﬁnal visit, and the most
frequent cause was chronic rejection. Some studies have
found an acute subclinical rejection in the evaluation of
pre-scheduled biopsies in patients with CKD in early stages
after transplantation. This ﬁnding predicts a lower survival of
the transplant.20 A recent controlled and randomised study
showed that early treatment for rejection improved the clin-
ical outcome of these patients.21 Therefore, a more precise
knowledge of the causes of CKD is required so an early diag-
nosis and treatment canbeapplied. Therefore, biopsies should
perform before the patient evolves to advanced CKD.
Some results conclude that an early biopsy that allows
microscopic evaluation and appropriate changes in immuno-
suppressive treatment may be helpful in protecting the graft
function.21
The recent cross-sectional ICEBERG22 study has shown that
the prevalence of CKD in kidney transplant recipients is ranges
from 35 and 55% depending on the diagnostic method, clini-
cal or objective criteria such as serum creatinine or GFR. This
study has also shown that CKD is a usually under-diagnosed
pathology in maintenance KT recipients. Doctors only detect
CKD in 4 out of the 10 patients that were diagnosed objec-
tively. Further, the results of OBSERVA conﬁrm that due to this
under-diagnosis, most transplanted patients do not receive
sufﬁcient treatment for comorbidities. Therefore, regarding
patients treatment there are considerable differences between
the clinical perceptions and the objective parameters and this
leads to signiﬁcant clinical inertia. Avoiding this clinical iner-
tia would be crucial in preserving kidney transplantfunction
by modifying the CNI if needed, performing timely biopsy,
adaptation of the immunosuppression therapy, treatment to
the CKD, control of comorbidities, and the addition of recom-
mendations for a healthy life style.23
Further, we have observed that there is a large percent-
age of patients with uncontrolled hypertension, which may
contribute to the increase of cardiovascular comorbidity and
comortality of the transplant recipients. More intense treat-
ment is required to improve the survival of the transplant and
the patients. According to current recommendations at the
time of the study, the optimum control of hypertension would
be a blood pressure <130/80mmHg or <125/75 in patients
with urine protein.24 These authors suggest a strict control of
hypertension to avoid clinical inertia in the kidney transplant
centers. Other authors also suggest that reduced GF does not
represent the total risk of presenting CKD,which suggests that
there are other factors, such as asymptomatic cardiopathy,
which could be involved in the gradual worsening of kidney
function and in the transplant failure.25 Likewise, recent stud-
ies carried out in the US have stressed the fact that there
is still an opportunity to improve the treatment and control
of traditional factors of cardiovascular risk in kidney trans-
plant recipients, as suggested by thehigh rates of uncontrolled
hypertension in these patients.26,27;35(3):256–263
Recent studies on kidney transplant recipients have shown
that there is poor control of cardiovascular risk factors.
In these studies, large differences have been observed in the
treatment of kidney transplant and non-transplanted patients
with the same stage of CKD.28,29 As compared with non-
transplanted CKD patients, kidney transplant recipients show
a poor control of blood pressure, lipids, and haemoglobin con-
centration. This data suggests that an adequate control of
these parameters is not achieved in the outpatient KT.
The KDIGO guidelines also provide suggestions for the
effective control of serum creatinine and proteinuria.30,31 The
level of serum creatinine one year after transplantion pre-
dicts poor outcome and may help determine the frequency
of visits in long term care. Proteinuria has been associ-
ated with cardiovascular complications and mortality in KT
patients. Therefore, the proteinuria measurement is recom-
mended one month after transplantation as an initial value,
and, every 3 months during the ﬁrst year, and annually
thereafter.32 It is further recommended to treat proteinuria
with renin–angiotensin inhibitors in an attempt to reduce
chronic kidney disease.33
Our study has several strong points, such as the large num-
ber of patients and participating centres, which represents the
populationof kidney transplant patients in Spain, and it reﬂect
the treatment of these patients in every day clinical practice.
Our study also has limitations, such as the short follow-up
period after the kidney transplant, only 6 months. However,
in patients with CKD grade 3, a follow-up of 6 months should
be enough to allow the result of speciﬁc medical interventions
directed to reduce worsening kidney function. Further, among
the limitations, it should be noted that among the causes for
progression of kidney failure, immunologic damage was not
included, although it is not the objective of this study, which
attempts to assess the clinical inertia in pathologies where
action is still possible by following the guidelines available.
In short, besides the treatment of proteinuria with
renin–angiotensin blockers, it is necessary a more rigorous
control other CKD markers, with assessment of biopsies,
long term follow-up, and speciﬁc strategies for the control of
comorbidity factors, to improve the clinical outcome and the
survival of maintenance kidney transplant recipients.34
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